In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease

In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease

Bibliographic Details
Main Authors:	Thomas Lund, Michael Tveden Gundesen, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Fredrik Schjesvold, Nordic Myeloma Study Group
Format:	Article
Language:	English
Published:	Nature Publishing Group 2024-04-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-024-01046-2

Similar Items

P919: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WITH ZOLEDRONIC ACID FOR FOUR YEARS INSTEAD OF TWO YEARS DECREASES RISK OF PROGRESSIVE BONE DISEASE WITHOUT INCREASING RISK OF OSTEONECROSIS OF THE JAW.
by: Michael Gundesen, et al.
Published: (2023-08-01)

Potential value of pre-planned imaging of bone disease in multiple myeloma
by: Michael T. Gundesen, et al.
Published: (2023-07-01)

Incidence and clinical characteristics of multiple myeloma with low M-protein levels and normal values of hemoglobin, creatinine, calcium, and serum free light chain ratio
by: Agoston Gyula Szabo, et al.
Published: (2021-04-01)

P875: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY
by: Frida Bugge Askeland, et al.
Published: (2023-08-01)

P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY
by: F. B. Askeland, et al.
Published: (2022-06-01)

Paired miRNA- and messenger RNA-sequencing identifies novel miRNA-mRNA interactions in multiple myeloma
by: Kristin Roseth Aass, et al.
Published: (2022-07-01)

Risk Factors and Risk Stratification of Thromboembolic Risk in Patients with Multiple Myeloma
by: Roza Chaireti, et al.
Published: (2022-08-01)

Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population.
by: Rasmus Sørrig, et al.
Published: (2017-01-01)

P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
by: Raija Silvennoinen, et al.
Published: (2023-08-01)

VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study
by: Jakob Nordberg Nørgaard, et al.
Published: (2024-04-01)

P969: VRD OUTPERFORMED VCD AS INDUCTION THERAPY BEFORE FIRST-LINE ASCT IN MULITPLE MYELOMA; RESULTS FROM A NATIONWIDE, POPULATION-BASED STUDY
by: Jakob Nordberg Nørgaard, et al.
Published: (2023-08-01)

Yearly zoledronic acid in postmenopausal osteoporosis.
by: Poole, K, et al.
Published: (2007)

Zoledronic Acid-Induced Insulitis in Rats
by: Heresh Rezaei, et al.
Published: (2023-06-01)

Inhibition of osteoblast activity by zoledronic acid
by: Fernanda Gonçalves Basso, et al.
Published: (2013-10-01)

ZOLEDRONATE-ASSOCIATED RECURRENCE OF OSTEONECROSIS OF JAWS
by: Rosen Tsolov, et al.
Published: (2020-10-01)

Zoledronic acid sequential to teriparatide may promote greater inhibition of bone resorption than zoledronic acid alone
by: Sharon Giveon, et al.
Published: (2023-11-01)

Zoledronic acid plus methylprednisolone zoledronic acid or placebo in symptomatic knee osteoarthritis: a randomized controlled trial
by: Guoqi Cai, et al.
Published: (2019-10-01)

Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
by: Ruxu You, et al.
Published: (2022-03-01)

Zoledronate prevents bone loss after stroke
by: Poole, K, et al.
Published: (2006)

Zoledronic acid in the treatment of osteoporosis: indications for use
by: Nataliya Vladimirovna Toroptsova, et al.
Published: (2011-06-01)

Identifying therapeutic biomarkers of zoledronic acid by metabolomics
by: Xiang Li, et al.
Published: (2023-04-01)

Acute uveitis following zoledronic acid infusion
by: Krishna Kumar Rathnam, et al.
Published: (2009-01-01)

Zoledronic acid in the treatment of osteoporosis: indications for use
by: Nataliya Vladimirovna Toroptsova, et al.
Published: (2011-06-01)

Role of zoledronic acid in the prevention and treatment of osteoporosis
by: Räkel A, et al.
Published: (2011-03-01)

Zoledronic acid infusion for prevention and treatment of osteoporosis
by: John A Sunyecz
Published: (2010-10-01)

Zoledronic acid induced unilateral anterior uveitis
by: Shipra Gupta, et al.
Published: (2020-01-01)

P950: COMBINED PROTEASOME AND AUTOPHAGY INHIBITION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA – A PHASE I TRIAL OF HYDROXYCHLOROQUINE, CARFILZOMIB AND DEXAMETHASONE
by: T. S. Slørdahl, et al.
Published: (2022-06-01)

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
by: Kazimierz Groen, et al.
Published: (2023-09-01)

Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial
by: Alexander Schmitz, et al.
Published: (2022-02-01)

FATIGUE AND OTHER SYMPTOMS FOLLOWING INTRAVENOUS ZOLEDRONATE THERAPY
by: Warburton, S, et al.
Published: (2009)

The effects of zoledronate on iliac bone remodelling in stroke patients
by: Poole, K, et al.
Published: (2007)

Zoledronate-induced scleritis: Clinical characteristics, management, and outcomes
by: Dan He, et al.
Published: (2025-01-01)

Generic zoledronic acid for osteoporosis: focus on tolerability and safety
by: N. V. Toroptsova, et al.
Published: (2021-10-01)

Effect of mevalonate, zoledronate and BCG on monocyte/macrophage phenotype
by: A. P. Lykov, et al.
Published: (2023-06-01)

An Unknown Side Effect of Zoledronic Acid: Acute Pancreatitis
by: Ayça Demirel, et al.
Published: (2024-10-01)

Use of Zoledronic Acid in Paediatric Craniofacial Fibrous Dysplasia
by: Chiara Di Pede, et al.
Published: (2016-01-01)

Role of zoledronic acid in treatment of osteoporosis and prevention of fractures
by: A. V. Krivova, et al.
Published: (2022-01-01)

Evaluation of the tolerability of zoledronic acid preparations for parenteral administration
by: I. A. Shafieva, et al.
Published: (2022-07-01)

How zoledronic acid improves osteoporosis by acting on osteoclasts
by: Biao Wang, et al.
Published: (2022-08-01)

Effects of zoledronic acid on osteoblasts in three-dimensional culture
by: Flora Thibaut, et al.
Published: (2015-03-01)